Director's Dealings

RNS Number : 4047X

hVIVO plc

10 August 2018

 

hVIVO PLC

("hVIVO" or the "Company")

 

Director's Dealings

London, UK, 10 August 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, was notified yesterday that on 9 August 2018, Dr Trevor Phillips, Executive Chairman of the Company, purchased 23,500 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 65.0 pence per share.

Following this transaction, Dr Phillips' total interest in the Company has increased by 23,500 Ordinary Shares to a total of 32,535 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Dr Trevor Phillips
2	Reason for the notification
a)	Position/ status	Executive Chairman
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Dr Trevor Phillips 65.0 23,500
e)	Aggregated information - Aggregated volume - Price - Aggregated total	23,500 65.0p £15,275.00
f)	Date of the transaction	9 August 2018
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc
Trevor Phillips (Executive Chairman)	[phone]
Fleur Wood (Director, Investor Relations)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell	[phone]

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.

 

END

 

 

DSHUGUBURUPRPGB